anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Apple and citrus are perennial tree fruit crops that are vital for nutritional security and agricultural economy and to achieve the Sustainable Development Goals of the United Nations. Apple scab and fire blight, along with Huanglongbing, canker, and tristeza virus, stand out as their most notorious diseases and annually destabilize fruit supply. An environmentally sound approach to managing these diseases is improving tree resistance through breeding and biotechnology. Perennial fruit tree germplasm collections are distributed globally and offer untapped potential as sources of resistance. However, long juvenility, specific pollination and flowering habits, and extensive outcrossing hinder apple and citrus breeding. Advances in breeding approaches include trans- and cis-genesis, genome editing, and rapid-cycle breeding, which, in addition to conventional crossbreeding, can all facilitate accelerated integration of resistance into elite germplasm. In addition, the global pool of available sources of resistance can be characterized by the existing genetic mapping and gene expression studies for accurate discovery of associated loci, genes, and markers to efficiently include these sources in breeding efforts. We discuss and propose a multitude of approaches to overcome the challenges of breeding for resistance in woody perennials and outline a technical path to reduce the time required for the ultimate deployment of disease-resistant cultivars.
A novel oside and aglycone of the empirical formulae C48H78O20 and C30H48O6 are isolated from the water-alcoholic steep liquor of the plant Centella Asiatica by concentration, crystallization, removal of the crystallization products, evaporation of the residual steep liquor to give the crude oside and, if desired, hydrolysis of this to the aglycone.  The oside is named Madecassoside and has a pasty melting-point at about 220 DEG  C. and [a ]20 of - 19 DEG (c=2.2,H2O). It is a triterpene derivative consisting of the triterpene acid (named Madecassic acid, of m.p. 256-268 DEG  C. and [a ]20+31 DEG  c=1.5, methanol), and probably one molecule of rhamnose and 2 molecules of glucose, linked as in gentiobiose. Methods for the purification of the oside are also described. Specification 923,414 is referred to.  The oside and the aglycone, which are stated to have anti-inflammatory properties and to be useful in the treatment of burns, wounds and ulcers, and of leprelcosis, and in the preparation of skin grafts, may be incorporated in pharmaceutical compositions for oral, parenteral or topical administration.
SYSTEM, APPARATUS AND METHOD  FOR DISPENSING MEDICATIONS ABSTRACT OF THE DISCLOSURE A   system,   apparatus   and   method   for dispensing medications  prescribed  by  a  doctor  or other  medical  personnel  is  disclosed.   A portable memory device  (such as a magnetic card)  is used to store  data  representing  prescription  information. Prescription information is encoded into the memory device  by  a  programming  device   located   in  a pharmacy.    A container  having  a  plurality  of individual  compartments  is  filled  at  the  pharmacy with medications in accordance with the prescription information.   The portable memory device and filled container  are  transported  together  to a medication dispenser  located  near  a  patient.   The  dispenser includes  apparatus  which  reads  the  prescription information   from  the   memory device   and   makes medications   within   the   individual   compartments available to the patient  only at prescribed times. The medication dispenser also includes apparatus for monitoring whether or not  the patient  is complying with the  prescribed  medication  schedule.   Patient compliance  information  is  stored  within  the  memory device.  The system also includes a monitor through which medical personnel can obtain a video display or printed record of  the  prescription  information and patient  compliance  information  stored  within  the memory device.
Anthraquinone dyes for hair are made by reacting halogenated, nitrated or sulphonated anthraquinones which may also contain one or two primary amino groups with mono- or polyglycols or their monoalkyl ehters or with thioglycols, for example by reacting dichlorinated 1 : 4 - diamino - anthraquinone or 1 : 4-diamino-5 - nitro - anthraquinone with ethyl diethylene glycol or monochlorinated 1 : 4-diamino - anthraquinone with sodium diethylene glycol, by reacting 1 : 4-diamino-anthraquinone with p-toluenesulphonic esters of monoethyldiethylene glycol or by reacting 1 : 4-diamino-2-bromoanthraquinone or 1 : 4 - diamino - 5 - nitroanthraquinone with NH(C2H4OC2H4OC2H5)2. Dyes if the following formulae are specified: <FORM:0957119/C3/1>ALSO:Hair such as human hair or fur is dyed by applying a dyeing agent containing an anthraquinone dye which is free from acid groups and has attached to the anthraquinone nucleus no hydroxyl groups but at least one aliphatic residue attached via a hetero-atom, the said aliphatic residue being (a) a hydroxy-alkyl or alkyl ether residue, the alkylene chain of which is interrupted at least once by a hetero-atom or in which ether residue the alkylene chain is attached to a cyclic ether group of (b) an alkyl residue on which the alkylene chain is interrupted by an acid amide group.  Representative of dyes specified are those of the formulae:-  <FORM:0957119/D1-D2/1> The dyeing agent may also contain wetting or washing agents such as alkylbenzene-sulphonates, fatty alcohol sulphates, alkyl sulphonates, fatty acid ethanolamides and addition products of ethylene oxide with fatty acids and fatty alcohols; permanent waving agents such as thioglycollic acid, thiolactic acid, mercaptopropane- and mercaptobutanesulphonic acids; thickeners such as methyl cellulose, starch, fatty alcohols, petroleum jelly, paraffin oil and fatty acids; and other dyes.  The dyeing agent may be in the form of a cream shampoo.  In examples the dyes are incorporated into creams containing cetyl-stearyl alcohol, coconut alcohol, fatty alcohol sulphate and ammonia, which may also contain sodium 2 : 4-dinitronaphthol sulphonate (3), the sodium salt of the mono-(4-amino-3-nitro-anilide) of maleic acid (5), 4-amino-3-nitro-phenyl urea (8) or ammonium thioglycollate (13) or in which the fatty alcohol sulphate is replaced by an ethylene oxide/fatty alcohol addition product (10).  In a further example the cream contains paraffin oil, fatty alcohol sulphate and ammonia. German Specification 1,087,565 is referred to.
BACKGROUND: Cardiogenic shock (CS) can stem from multiple causes and portends poor prognosis. Prior studies have focused on acute myocardial infarction-CS; however, acute decompensated heart failure (ADHF)-CS accounts for most cases. We studied patients suffering ADHF-CS to identify clinical factors, early in their trajectory, associated with a higher probability of successful outcomes.
METHODS: Consecutive patients with CS were evaluated (N=1162). We studied patients who developed ADHF-CS at our hospital (N=562). Primary end point was native heart survival (NHS), defined as survival to discharge without receiving advanced HF therapies. Secondary end points were adverse events, survival, major cardiac interventions, and hospital readmissions within 1 year following index hospitalization discharge. Association of clinical data with NHS was analyzed using logistic regression.
RESULTS: Overall, 357 (63.5%) patients achieved NHS, 165 (29.2%) died, and 41 (7.3%) were discharged post advanced HF therapies. Of 398 discharged patients (70.8%), 303 (53.9%) were alive at 1 year. Patients with NHS less commonly suffered cardiac arrest, underwent intubation or pulmonary artery catheter placement, or received temporary mechanical circulatory support, had better hemodynamic and echocardiographic profiles, and had a lower vasoactive-inotropic score at shock onset. Bleeding, hemorrhagic stroke, hemolysis in patients with mechanical circulatory support, and acute kidney injury requiring renal replacement therapy were less common compared with patients who died or received advanced HF therapies. After multivariable adjustments, clinical variables associated with NHS likelihood included younger age, history of systemic hypertension, absence of cardiac arrest or acute kidney injury requiring renal replacement therapy, lower pulmonary capillary wedge pressure and vasoactive-inotropic score, and higher tricuspid annular plane systolic excursion at shock onset (all P<0.05).
CONCLUSIONS: By studying contemporary patients with ADHF-CS, we identified clinical factors that can inform clinical management and provide future research targets. Right ventricular function, renal function, pulmonary artery catheter placement, and type and timing of temporary mechanical circulatory support warrant further investigation to improve outcomes of this devastating condition.
Patients in his groups will performed home-based rehabilitation in the early stages of the post-op period. They will com to our clinic once in a two weeks and the recieve the exercise program to perform at home until the 6. weeks of the post-operative period. After the 6. week they will come to our clinic once in a week until the post-operative 12. week.
PURPOSE:To store livestock semen keeping the activity of the semen for a long time with little damage of the semen, with a simple refrigeration process, by contacting the livestock semen with Ringer's solution containing albumin or activated charcoal interposing a dialysis membrane therebetween. CONSTITUTION:For example, livestock semen 8 is placed ina dialysis membrane tube 2 and sealed with a cap 5. At the same time, the space between the dialysis membrane tube 2 and the vessel 1 is filled with Ringer's solution containing albumin or activated charcoal, and sealed. That is to say, the semen for the artificial conception of livestock, esp. pig, is stored in contact with the Ringer's solution interposing a dialysis membrane therebetween. The storage temperature is pref. about 15 deg.C. The harmful substance formed in the semen at about 15 deg.C can be removed by albumin or activated charcoal through the dialysis membrane, and the semen can be effectively stored. A commercial dialysis membrane for artificial kidney or a porous film can be used as the dialysis membrane.
The purpose of this Phase II study you are being asked to participate in will assess the effectiveness of the combination of oral cyclophosphamide and sirolimus in sarcoma patients with relapsed or widespread disease who cannot be cured by surgery, radiation or conventional chemotherapy. Malignant connective tissue tumors of soft tissue and bone (sarcomas) are highly aggressive cancers. There are few available chemotherapy treatments that are active in treating sarcomas. Sarcomas that have metastasized (spread throughout the body) are usually fatal. There is a great need to identify new active drugs to treat metastatic or relapsed sarcomas. Low dose oral daily cyclophosphamide is an established chemotherapy regimen for treatment of malignant and autoimmune disease and is generally well tolerated. Sirolimus is approved for prevention of kidney rejection after transplantation. Temsirolimus, a form of sirolimus, is approved for the treatment of kidney cancer. Sirolimus combined with cyclophosphamide in animal models of sarcoma resulted in significant anti-tumor activity. Tumor and blood samples will be studied to look for known protein targets of the medication to help learn why certain subjects have a favorable response to the treatment.
INTRODUCTION: Periostin is a matricellular protein. Elevated serum concentrations of periostin have been reported in patients with various cardiovascular diseases, including heart failure. Patients with end-stage renal disease have a substantially increased risk for cardiovascular diseases. However, there is a lack of clinical studies to clarify the prognostic significance of systemic periostin on all-cause mortality in patients with end-stage renal disease on hemodialysis.
METHODS: 313 stable end-stage renal disease patients were recruited and followed for 5 years concerning all-cause mortality. At baseline, we collected blood samples and clinical data. Serum periostin concentrations were measured using a certified ELISA.
RESULTS: The optimal cut-off value for serum periostin regarding all-cause mortality, calculated through receiver operating characteristic analysis, was 777.5 pmol/L. Kaplan-Meier survival analysis using this cut-off value demonstrated that higher periostin concentrations are linked to higher all-cause mortality (log-rank test: p = 0.002). Subgroup analysis revealed that serum periostin concentrations only affected all-cause mortality in male but not in female patients (p = 0.002 in male patients and p = 0.474 in female patients). Multivariate Cox regression analyses, adjusted for confounding factors, likewise showed that elevated serum periostin concentrations were positively associated with all-cause mortality in male (p = 0.028) but not in female patients on hemodialysis (p = 0.313).
CONCLUSION: Baseline serum periostin is an independent risk factor for all-cause mortality in male patients with chronic renal disease on hemodialysis.
BACKGROUND: Circular RNAs (circRNAs) are associated with development and progression of multiple myeloma (MM). However, the role and mechanism of circ_0005615 in MM have not been elucidated.
METHODS: Circ_0005615 was determined by GEO database. quantitative RT-PCR was performed to confirm the expression of circ_0005615 in peripheral blood of MM patients and MM cells. The roles of circ_0005615 in MM were analyzed using CCK8, transwell invasion, cell apoptosis and tumor xenograft experiments. Bioinformatics tools, RIP and RNA pull down assays were conducted to explore the downstream of circ_0005615. Furthermore, the mechanism was investigated by quantitative RT-PCR, western blot, dot blot and meRIP-PCR assays.
RESULTS: Circ_0005615 was upregulated in MM. Overexpression of circ_0005615 promoted cell viability and invasion, and suppressed apoptosis in vitro, which were opposite when circ_0005615 was knockdowned. Mechanistically, EIF4A3, a RNA-binding protein (RBP), could directly bind to circ_0005615 and ALKBH5, where ALKBH5 could directly combine with MAP3K4, forming a circ_0005615- EIF4A3-ALKBH5-MAP3K4 module. Furthermore, circ_0005615 overexpression increased m6A methylation of MAP3K4 by inhibiting ALKBH5, leading to decreased MAP3K4. Further functional experiments indicated that ALKBH5 overexpression weakened the promoting roles of circ_0005615 overexpression in MAP3K4 m6A methylation and tumor progression in MM. The above functions and mechanism were also verified in vivo.
CONCLUSIONS: Elevated circ_0005615 decreased MAP3K4 mediated by ALKBH5 through interacting with EIF4A3, thereby accelerating MM progression. Circ_0005615 might be a promising biomarker and target of MM.
Nanoparticles include a core and one or more targeting moieties, as well as one or more contrast agents or one or more therapeutic agents. The contrast agents or therapeutic agents may be contained or embedded within the core. If the nanoparticle includes therapeutic agents, the agents are preferably released from the core at a desired rate. The core may be biodegradable and may release the agents as the core is degraded or eroded. The targeting moieties preferably extend outwardly from the core so that they are available for interaction with cellular components, which interactions will target the nanoparticles to the appropriate cells, such as apoptotic cells; organelles, such as mitochondria; or the like. The targeting moieties may be tethered to the core or components that interact with the core.
FIELD: medicine. SUBSTANCE: essence of this method resides in extracting silt using mixture of ethyl alcohol and liquid carbonic acid. Concentration of ethyl alcohol must be between 19 and 49 %. Final step is distillation of alcohol. EFFECT: yield of end product increased from 2.54 to 2.95 g plus rejection of toxic solutions. 2 tbl
Healthy obese individuals (n=20) defined with a Body Mass Index (BMI) ≥ 95th percentile for age/sex will be recruited. Participants in this cohort will be asked to complete a one-time study visit.
FIELD: biotechnology, veterinary science. SUBSTANCE: strain of bacterium Pseudomonas aeruginosa ЛO 1  is deposited in collection of strains that are pathogens of diseases in fur wild animals of museum bacterial and viral cultures named for V. A. Afanasiev and has registration number ЛO 1 . Strain relates to serovariant 01. Strain is cultured in Marten's broth or synthetic medium at 32 C for 18-20 h at constant shaking. After control of grown culture for toxicogenicity and proteolytic activity bacterial mass is separated and inactivated. Then aluminum hydroxide is added as an adjuvant and packaged. Invention ensures to prevent the concealed loss in reproduction of fur wild animals in farms with pyocyanic infection being independently of serological pattern of pathogen. EFFECT: strain indicated above, enhanced effectiveness of vaccine.
Nutrition-focused interventions are essential to optimize the bariatric care process and improve health and weight outcomes over time. Clear and detailed reporting of these interventions in research reports is crucial for understanding and applying the findings effectively in clinical practice and research replication. Given the importance of reporting transparency in research, this study aimed to use the Template for Intervention Description and Replication (TIDieR) checklist to evaluate the completeness of intervention reporting in nutritional weight management interventions adjunct to metabolic and bariatric surgery (MBS). The secondary aim was to examine the factors associated with better reporting. A literature search in PubMed, PsychINFO, EMBASE, Scopus, and the Cochrane Controlled Register of Trials was conducted to include randomized controlled trials (RCT), quasi-RCTs and parallel group trials. A total of 22 trials were included in the final analysis. Among the TIDieR 12 items, 6.6 ± 1.9 items were fully reported by all studies. None of the studies completely reported all intervention descriptors. The main areas where reporting required improvement were providing adequate details of the materials and procedures of the interventions, intervention personalization, and intervention modifications during the study. The quality of intervention reporting remained the same after vs. before the release of the TIDieR guidelines. Receiving funds from industrial organizations (p = 0.02) and having the study recorded within a registry platform (p = 0.08) were associated with better intervention reporting. Nutritional weight management interventions in MBS care are still below the desirable standards for reporting. The present study highlights the need to improve adequate reporting of such interventions, which would allow for greater replicability, evaluation through evidence synthesis studies, and transferability into clinical practice.
L-NMMA and pembrolizumab will be administered for 6 cycles. Cycle length will be 21 days. L-NMMA will be administered as a 2-hour intravenous (IV) infusion on Days 1-5 at each cycle. The dose levels of L-NMMA are as follows: Dose Level -1, 12.5 mg/kg; Dose Level 0 (starting dose), 15.0 mg/kg; and Dose Level 1, 20 mg/kg. L-NMMA dose will escalate/de-escalate based on the occurrence of dose-limiting toxicities. Pembrolizumab at a fixed dose of 200 mg will be IV infused over 30 minutes on Day 5 at each cycle. Pembrolizumab will be administered 1 hour after L-NMMA infusion on Day 5 at each cycle. Subjects without disease progression after 6 cycles of L-NMMA and pembrolizumab will continue pembrolizumab until disease progression or unacceptable AEs.
Melanomas arise from transformed melanocytes, positioned at the dermal-epidermal junction in the basal layer of the epidermis. Melanocytes are completely surrounded by keratinocyte neighbors, with which they communicate through direct contact and paracrine signaling to maintain normal growth control and homeostasis. UV radiation from sunlight reshapes this communication network to drive a protective tanning response. However, repeated rounds of sun exposure result in accumulation of mutations in melanocytes that have been considered as primary drivers of melanoma initiation and progression. It is now clear that mutations in melanocytes are not sufficient to drive tumor formation-the tumor environment plays a critical role. This review focuses on changes in melanocyte-keratinocyte communication that contribute to melanoma initiation and progression, with a particular focus on recent mechanistic insights that lay a foundation for developing new ways to intercept melanoma development.
The ill effects of ISDN overdose are generally the results of ISDN's capacity to induce vasodilatation, venous pooling, reduced cardiac output, and hypotension. These hemodynamic changes may have protean manifestations, including increased intracranial pressure, with any or all of persistent throbbing headache, confusion, and moderate fever; vertigo; palpitations: visual disturbances: nausea and vomiting (possibly with colic and even bloody diarrhea); syncope (especially in the upright posture); air hunger and dyspnea, later followed by reduced ventilatory effort; diaphoresis, with the skin either flushed or cold and clammy; heart block and bradycardia; paralysis; coma; seizures; and death.

Laboratory determinations of serum levels of ISDN and it metabolites are not widely available, and such determinations have, in any event, no established role in the management of ISDN overdose.

There are no data suggesting what dose of ISDN is likely to be life-threatening in humans. In rats, the median acute lethal dose (LD50) was found to be 1100 mg/kg.

No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of ISDN and its active metabolites. Similarly, it is not known which, if any, of these substances can usefully be removed from the body by hemodialysis.

No specific antagonist to the vasodilator effects of ISDN is known, and no intervention has been subject to controlled studies as a therapy for ISDN overdose. Because the hypotension associated with ISDN overdose is the result of venodilatation and arterial hypovolemia, prudent therapy in this situation should be directed toward increase in central fluid volume. Passive elevation of the patient's legs may be sufficient, but intravenous infusion of normal saline or similar fluid may also be necessary.

The use of epinephrine or other arterial vasoconstrictors in this setting is likely to do more harm than good.

In patients with renal disease or congestive heart failure, therapy resulting in central volume expansion is not without hazard. Treatment of ISDN overdose in these patients may be subtle and difficult, and invasive monitoring may be required.
INTRODUCTION: Wiedemann-Steiner syndrome (WSS) is a rare autosomal-dominant disorder caused by KMT2A variants. The aim of this study was to characterize a novel KMT2A variant in a child with WSS and demonstrate integrated diagnostic approaches.
METHODS: A 3-year-old female with developmental delay, distinctive facial features, and anal fistula underwent whole exome sequencing (WES). RNA analysis was performed to assess splicing effects caused by a novel variant.
RESULTS: WES identified novel heterozygous KMT2A c.5664+6T>C variant initially classified as a variant of uncertain significance. RNA analysis provided evidence of aberrant splicing (exon 20 skipping), allowing reclassification to likely pathogenic. The patient exhibited typical WSS features along with a potential novel finding of anal fistula.
CONCLUSION: This report describes a novel non-canonical splice site variant in KMT2A associated with WSS. RNA analysis was critical for variant reclassification. Detailed phenotypic evaluation revealed common and expanded WSS manifestations. This case highlights the importance of combining clinical assessment, DNA testing, and RNA functional assays for the diagnosis of rare genetic disorders.